INTRODUCTION
Fenofibric acid (FA), the active moiety of fenofibrate, is an antihyperlipidemic agent because it is the synthetic ligand that binds to nuclear peroxisome proliferatoractivated receptors alpha (PPARα) [1] [2] [3] . FA is a carboxylic acid moiety, while fenofibrate is an ester moiety 4 . Figure 1 shows the chemical structures of both FA and fenofibrate. In its marketed form, fenofibrate is insoluble and recommended to take with food, and it typically includes non-micronized tablets, micronized capsules, micro-coated micronized tablets, and hard gelatin capsules. The nanocrystal formulation of fenofibrate and the conventional formulation of FA currently available in the market can be taken with or without food 3 . A single 105-mg dose of FA is bioequivalent to a single 145-mg dose of fenofibrate in both fed and fasted states 5 .
Not only is the production of the nanocrystal formulation of fenofibrate inflexible, but the expensive cost is also necessary to take into account. As a result, FA has been chosen and developed as an alternative to fenofibrate for oral administration.
Like fenofibrate, FA mainly absorbed from the gastrointestinal (GI) tract. However, it does better than the first, causing its bioavailability to be higher than that of fenofibrate in all GI regions 6 . The absolute oral bioavailability of FA in rats stands at 40% 7 . Physicochemically, FA is characterized as a poorly soluble weak acid drug.
The pKa of FA is determined 4, and the log P is calculated 3.85 8 . FA has relatively poor solubility at gastric pH (the pH is lower than its pKa), but it has fairly good solubility at intestinal pH 1 . The solubility of FA is 162.5 µg/ml in water and 1156 µg/ml at pH 6.8 9 . Due to its adequate permeability, FA is classified as a class II drug in the Biopharmaceutical Classification System (BCS) subclass (a) for the weak acid 10 . The poor solubility of FA in water may cause its dissolution to be reasonably slow and its bioavailability to be unpredictable.
Recently, FA is commercially available as a tablet formulation, namely Fibricor ® (the brand for 105-mg FA). The weight of this formulation is 840 mg and consists of so many ingredients for the active substance of 105 mg. The dosage form of FA with the increased dissolution is developed to examine other possible platforms. The dissolution rate of BCS class II drugs is the limiting step for their oral bioavailability.
The surface solid dispersion formulation is accepted as a method to improve the dissolution rate and bioavailability of poorly soluble drugs. The distribution of drug particles on the carrier surface can enhance wettability, dissolution rate, and u n c o r r e c t e d p r o o f consequently bioavailability of drugs 11, 12 . The FA surface solid dispersion has been investigated. In the simulated intestinal fluid, the data showed that the dissolution of FA increased more than that of the pure drug 13 . In this study, a new FA formulation with enhanced dissolution and less inactive ingredients was developed and evaluated for the in vitro and in vivo performance, which has never appeared in any publication.
The drug dissolution rate and bioavailability are influenced by the manufacturing process and the changes happening during the formulation. Therefore, bioavailability issues are frequently used to assess the safety and efficacy of drug products. Only two studies have been reported so far to enhance the dissolution and bioavailability of FA. The FA-loaded pellet is prepared with magnesium carbonate and kcarrageenan employing the extrusion/spheronizing technique followed by coating with ethyl cellulose. The pellet is bioequivalent to the commercial product in beagle dogs 14 . Additionally, the mixture of FA and magnesium carbonate at a weight ratio of 2/1 can improve the solubility, dissolution, and oral bioavailability of FA 
MATERIAL AND METHODS

Materials
The FA and the standard FA used in this study were purchased from BOC Science 
Methods
Preparation of surface solid dispersion and conventional formulations
The SSD formulation of FA with CS (1:1 w/w) was prepared by the solvent evaporation method. At first, the drug was dissolved in ethanol to obtain a clear solution. The carrier CS was then dispersed in the drug solution, and the solvent was removed using a rotary evaporator. The viscous residues produced were made dry in an oven with a temperature of 40°C to allow complete evaporation of ethanol in order to obtain the constant weight of powder. Subsequently, the mass was passed through a 40-mesh sieve to get dry free-flowing powder ready for compression into tablets by the direct compression method. Avicel PH 101 and magnesium stearate (1% w/w) were later added as a diluent and lubricant. The characteristic of this mixture was checked out for flowability and compressibility before the compression of this mass into tablets was conducted. The blend was compressed by a single punch tablet press with punch size 10 mm into 300-mg tablets with the FA concentration of 105 mg.
The conventional formulation was prepared by the wet granulation method. The drug was mixed thoroughly with lactose monohydrate as a diluent and then granulated with starch paste 10% w/w. The dried granules were incorporated with dried starch (10% w/w), magnesium stearate (1% w/w), and talc (2% w/w). The same procedures u n c o r r e c t e d p r o o f of flowability, compressibility, and compression also applies to this mixture with the same tablet press, punch size, and FA concentration.
Besides the above formulations, the reference formulation of FA was also used in this study. FA ® itself is actually a generic version of Fibricor ® , whose formulation contains fenofibric acid, copovidone, crospovidone, magnesium stearate, and microcrystalline cellulose in its 840-mg tablet weight.
Drug content uniformity in tablet formulations
In each formulation, the tablet samples were weighed accurately and transferred into a 100-mL volumetric flask. The solvent mixture of 2 M urea and 1 M sodium citrate (5 mL each) was added, and the mixture was heated for 15 minutes. This procedure was performed for the solubilization of FA, and the solvent mixture was used as a hydrotropic agent 15 . The solution was eventually filtered through a Whatman filter paper, while the remaining filtrate was diluted with distilled water and analyzed by using a UV/Vis Spectrophotometer (Shimadzu 1800A) at 299 nm. The FA concentration was determined based on the calibration curve previously built. The experiment with the drug content was repeated three times, and the results were expressed as the mean ± standard deviation (SD).
Dissolution studies
The release characteristics of the tested formulations and the reference formulation were evaluated for the dissolution rate in Type 2 (paddle) dissolution apparatus (Electrolab TDT-08L, USP), using 500 ml of phosphate buffer pH 6.8, and the biorelevant medium FaSSIF was maintained at 37 ± 0.5 °C. The paddle rotation speed was set at 50, 75 and 100 rpm. The samples were taken at specified time Clinical Practice (ICH-GCP) guidelines. There were nine eligible subjects used in this study. The subjects taken were all healthy and male. The age of participants varies from 22 to 48 years, weight from 47 to 68 kg, and height from 155 to 175 cm. These criteria follow the standard body mass index 18-25 kg/m 2 . Besides, they were required not to have any significant medical history and evidence of hepatic, renal, gastrointestinal, or hematological disorders; acute or chronic diseases; clinically significant abnormalities; or drug abuse or allergy. Also, they were instructed to abstain from taking any concomitant medication, food supplement, or herbal medicine for at least 14 days prior to and during the study. The exclusion was made to those who participated in any clinical study or used investigational drugs within the past 30 days prior to starting this study. In addition to it, caffeine-containing beverages were not allowed during the study being conducted. All chosen participants were given written informed consent forms after the nature and purpose of the study was explained.
The protocol applied the randomized, three-way crossover design with nine subjects in each period. In the first period, after an overnight fasting and a pre-dose blood sampling, every subject was given a single dose of any formulation in a random way along with 250 ml of water. Food and drinks (other than water 2 hours after dosing)
were not allowed until 4 hours after dosing. Standard meals for both lunch and dinner were served at the 4th and 10th hour respectively, while snack at the 8th hour after drug administration. Blood pressure, heart rate, respiration rate, and adverse events were monitored during blood sampling. Approximately 5 ml of the serial venous blood samples were drawn using drawing needles 22G into vacuette tubes 
HPLC Assay
The concentration of FA in plasma was determined using the HPLC method, developed and validated by Shah et al., 2014 16 . CFHB was used as the internal standard (IS). The method has been verified before being used in the study. Stock solutions of 1 mg/mL were prepared for FA and CFHB respectively and were diluted in methanol to obtain seven FA-containing standard solutions of 0.05-20 µg/mL and one IS-containing solution of 250 µg/mL. All of these solutions were then stored at the temperature of -20°C. The calibration curve was established by spiking the working standard solutions (50 µL) and the IS solution (50 µL) into drug-free human plasmas (450 µL). In relation to the concentration, matrix-matched FA solutions were prepared in plasmas at various concentrations of 0.05, 0.1, 0.5, 1, 5, 10, 20 µg/mL, whereas IS solution was at concentration 250 µg/mL. The similar method was employed to prepare for QC samples in human plasmas. In this study, four additional QC samples were of 0.05, 0.5, 10 and 15µg/mL.
The analytical separation was performed on an Inertsil® C18 (4.6 x 150 mm, Waters) column, and the mobile phase was the gradient of acetonitrile and 0.01 M phosphate buffer pH 2.8 (75:25), with the flow rate of 1 mL/min which runs for 7 minutes. The samples were detected at 287 nm (Waters 2487 dual λ absorbance detector). The retention times for both FA and CFHB as the IS were 3.5 and 5.5 min respectively.
No interfering peaks were observed at both retention times. A typical chromatogram is shown in Figure 2 
Plasma sample and preparation
Samples were prepared using the liquid-liquid extraction technique. Into 500 µL plasma sample, 50 µL of IS solution (250 µg/mL) and 1 mL of 1 N HCl were added and mixed for 30 seconds in a vortex mixer. Three mL of ethyl acetate was put on, and the mixture was mixed in a roller mixer for 30 minutes, followed by centrifugation for 15 minutes at 5000xg. The top organic layer was separated and evaporated for u n c o r r e c t e d p r o o f drying at 40°C using a stream of nitrogen. The residue was reconstituted in 100 µL of the mobile phase, and 60 µL was injected into the HPLC system (Waters 1525 binary pump).
Dissolution data analysis
Dissolution efficiency (DE) was used for comparison of dissolution rates, calculated from the area under the dissolution curves at 60 minutes, and expressed as a percentage of the rectangle area described by 100% dissolution within the same time. ANOVA was used to compare the DE of test and reference tablets profiles at 60 min (α = 0.05).
Pharmacokinetic analysis
The pharmacokinetic parameters were calculated by a non-compartmental method. 
Statistical analysis
For the parameters of AUC0-t, AUC0-∞, Cmax, Tmax, and t1/2, an analysis of variance (ANOVA) was applied for untransformed data. The level of significance was α = 0.05 and a p-value of < 0.05 was considered to be statistically significant.
Correlation development
The principle of statistical moment analysis was utilized to asses the correlation of 
RESULTS
In vitro studies
All products fulfilled the general pharmaceutical requirements for weight variation, content assay, and content uniformity assay. The prepared tablets complied with the official specifications for disintegration time, hardness, and friability. The in vitro dissolutions were conducted in two different medium (phosphate buffer pH 6.8 and biorelevant FaSSIF) and each at three different rotation speed to determine dissolution profile under various conditions.
The in vitro dissolution profiles of the SSD (F1) and conventional formulations (F2) are presented in Figure 3 , and the summary of the mean DE60 of all FA tablets is given in Table 1 . Significant differences existed between F1: F2 and F2: FA® at all conditions, whereas no significant difference arose from F1: FA® for 5 conditions.
In vivo studies
The concentration-time profiles of oral administration of both the SSD and conventional formulations and the reference formulation are depicted in Figure 4 . All formulations resulted in an identic curve of plasma drug concentration versus time.
The mean pharmacokinetic parameters of all FA tablets are summarized in Table 2 .
No significant difference was seen for all pharmacokinetic parameters from those formulations.
In vitro-in vivo relationship
Statistical moment analysis has been suggested as a better parameter to examine the IVIVC. A poor correlation between in vivo MRT and in vitro MDT for the three formulations was found in this study ( Figure 5 ).
DISCUSSION
The new formulation of FA, a BCS Class II drug, was developed in this study and selected as an alternative to fenofibrate for oral administration. The SSD formulation was prepared by the solvent evaporation method to increase the dissolution of FA and compared to conventional and reference formulation. A conventional formulation of FA was prepared using wet granulation method. All of these formulations met the general pharmaceutical requirements for physicochemical properties. However, u n c o r r e c t e d p r o o f significant differences were observed between both. The SSD formulation (F1) led to an instantaneous dissolution of the drug, releasing approximately 90% within the first five minutes at 75 and 100 rpm conditions. In contrast, the conventional formulation (F2) released nearly 80% of the drug within 45 minutes. Meanwhile, the reference formulation (FA ® ) yielded the same dissolution as the F1. The FA dissolution from F1 increased due to the presence of the polymer and physical structure of the SSD. In this case, FA was dispersed well on the CS surface, and the fine particles were able to increase its surface area for solubilization. When the CS contacted the dissolution medium, it became swelling and made it possible for FA to be wet to dissolve in the media. The swelling of the CS caused the cluster deaggregation of the drug particles and facilitated the dissolution process. Meanwhile, F2 could not achieve rapid dissolution despite the fact that around 80% of the drug dissolved within 45 min, and it satisfied the requirement for immediate drug release dosage form. Based on the data of the in vitro dissolution, there were significant differences found in the dissolution performances and therefore included in the development of the IVIVC.
The mean of all pharmacokinetic parameters from each product was not statistically different (p > 0.05), suggesting that the plasma profiles generated by FA Figure 4 and Table 2 .
Apparently, the dissolution media in this study did not completely simulate the conditions of the GI tract. It is reported that biorelevant dissolution medium have ability to predict well the in vivo performances of insoluble drugs. However, that purpose is not achieved in this study. Further studies are suggested to use biorelevant pH-gradient methods to obtain a strong IVIVC.
In most cases, statistically significant differences of in vivo MRT among various formulations were not significant enough to produce a strong correlation between MRT and MDT. For a 105-mg dose of FA and aqueous solubility of 0.162 mg/mL, 650 mL of fluid was required to dissolve a single dose. Therefore, the volume of water taken initially not only dissolved the drug to a great extent but also decreased the dependency of drug absorption to the drug dissolution 17 . This phenomenon led to a nil correlation in this study. The fact that the in vitro differences in the early dissolution were not realized into the in vivo differences attributed to the continuous excretion of bile that happened in the GI tract 18 . There was still a possibility that FA absorbed with the help of a transporter (facilitated transport) and or energy (active transport). However, the amount was likely to be limited, even if much was dissolved.
STUDY LIMITATION
The present study limited on using a single medium method for dissolution testing.
Further studies are suggested to use biorelevant pH-gradient methods to obtain a strong IVIVC.
CONCLUSION
The in vitro dissolution behavior of fenofibric acid using single medium did not reflect their in vivo properties at the fasted condition. There was no correlation between the in vitro dissolution and the in vivo bioavailability of fenofibric acid at this condition. 
